This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NVO, LLY Slip After Study Links Obesity Drug Use to Vision Loss
by Sundeep Ganoria
A new study led by investigators of a Harvard-affiliated teaching hospital found that Novo Nordisk's (NVO) GLP-1 drugs Ozempic and Wegovy could be linked to rare cases of vision loss.
Eli Lilly (LLY) Gets FDA Nod for Alzheimer's Drug Donanemab
by Zacks Equity Research
Eli Lilly's (LLY) Alzheimer's disease drug, Kisunla (donanemab), wins FDA approval. Kisunla will be the second drug on the market to treat the disease.
Viking (VKTX) Skyrockets 197% YTD: Is the Stock Worth a Buy?
by Sundeep Ganoria
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
5 Top-Performing S&P 500 Stocks of 1H Set to Shine Further
by Sweta Killa
The S&P 500 wraps up the first half with gains of 14%, representing one of the strongest performances since the late-1990s dot-com bubble.
HIMS Stock Tumbles: Here's Why It's a Buy Right Now
by Ethan Feller
Hims & Hers Health is a high growth, healthcare startup stepping into the GLP-1 space.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Eli Lilly (LLY) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
In the most recent trading session, Eli Lilly (LLY) closed at $901.26, indicating a -0.37% shift from the previous trading day.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day.
Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion
by Zacks Equity Research
Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.
Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?
by Kinjel Shah
Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.
Company News for Jun 25, 2024
by Zacks Equity Research
Companies In The News Are: RXO, UPS, LLY, ALNY, META, AAPL.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Here's How Much a $1000 Investment in Eli Lilly Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
The Zacks Analyst Blog Highlights Pfizer, Johnson & Johnson and Eli Lilly
by Zacks Equity Research
Pfizer, Johnson & Johnson and Eli Lilly are part of the Zacks top Analyst Blog.
Eli Lilly (LLY) Registers a Bigger Fall Than the Market: Important Facts to Note
by Zacks Equity Research
The latest trading day saw Eli Lilly (LLY) settling at $885.99, representing a -0.61% change from its previous close.
Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Can Eli Lilly ETFs Surge on Approval of Alzheimer's Drug?
by Sanghamitra Saha
On Jun 10, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted 11-0, unanimously recommending the approval of Eli Lilly's (LLY) Alzheimer's disease drug, donanemab.
Should You Invest in the iShares U.S. Pharmaceuticals ETF (IHE)?
by Zacks Equity Research
Sector ETF report for IHE
The Zacks Analyst Blog Highlights Berkshire Hathaway, Eli Lilly, PepsiCo, Hovnanian and IDT
by Zacks Equity Research
Berkshire Hathaway, Eli Lilly, PepsiCo, Hovnanian and IDT are part of the Zacks top Analyst Blog.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Top Stock Reports for Berkshire Hathaway, Eli Lilly & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Berkshire Hathaway Inc. (BRK.B), Eli Lilly and Company (LLY) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Hovnanian Enterprises, Inc. (HOV) and IDT Corporation (IDT).
Alzheimer's in Focus as FDA Panel Endorses Lilly's Donanemab (Revised)
by Zacks Equity Research
If Eli Lilly's (LLY) donanemab is approved by the FDA, it will become the second drug approved by the FDA to reduce the clinical decline associated with Alzheimer's disease.
The Zacks Analyst Blog Highlights Biogen, Eli Lilly's, Prothena and AC Immune (Revised)
by Zacks Equity Research
Biogen, Eli Lilly's, Prothena and AC Immune are included in this Analyst Blog.
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
by Kinjel Shah
An FDA panel endorses Eli Lilly's (LLY) Alzheimer's disease drug, donanemab. Pfizer's (PFE) DMD study on investigational gene therapy fails.